Literature DB >> 1408348

Chronic peroral immunization of conventional laboratory rats with mutans streptococci leads to stable acquired suppression of salivary antibodies.

G R Riviere1, M A Wagoner, I L Freeman.   

Abstract

Prior investigations have demonstrated that salivary antibody responses to mutans streptococci are dose-dependent and temporary. The purpose of this study was to evaluate the stability of antibody suppression established by mutans streptococci. Streptococcus mutans 6715-15 was provided in food to conventional rats for 18 weeks. Antigen was withdrawn for 10 weeks and then resumed for an additional 6 weeks. Saliva and serum from nonimmunized controls and from experimental rats were tested with a quantitative enzyme-linked immunosorbent assay for IgA and IgG antibodies to whole bacterial cells and to soluble antigen. Results show that salivary antibodies were stimulated by primary peroral immunization, that IgA was the dominant isotype and that IgA antibodies were primarily directed against soluble antigen. This study also shows that immunity is not maintained, even while challenge continues, and that once suppression is established, immunized animals do not recover their ability to respond, even if exposure is stopped for 10 weeks before re-exposure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1408348     DOI: 10.1111/j.1399-302x.1992.tb00526.x

Source DB:  PubMed          Journal:  Oral Microbiol Immunol        ISSN: 0902-0055


  3 in total

1.  In vivo IgA coating of anaerobic bacteria in human faeces.

Authors:  L A van der Waaij; P C Limburg; G Mesander; D van der Waaij
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

2.  No apparent influence of immunoglobulins on indigenous oral and intestinal microbiota of mice.

Authors:  H Marcotte; M C Lavoie
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 3.  Oral microbial ecology and the role of salivary immunoglobulin A.

Authors:  H Marcotte; M C Lavoie
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.